Microvascular disease confers additional risk to COVID-19 infection
Microvascular disease confers additional risk to COVID-19 infection
复制标题
DOI：
10.1016/j.mehy.2020.109999
复制
发表时间：
2020-11-01
影响因子：
4.7
通讯作者：
Vigerust, David John
中科院分区：
文献类型：
--
作者：
Bale, Bradley Field;Doneen, Amy Lynn;Vigerust, David John
截至目前，COVID-19大流行中的大多数死亡病例均归因于肺炎。正如预期的那样，中国报告的慢性肺病患者（6.3%）和癌症患者（5.6%）的死亡率较高。根据美国心脏病学会临床公报“CV护理团队COVID-19临床指南”，老年人（70-79岁8.0%; ≥ 80岁14.8%）、糖尿病患者（7.3%）、高血压患者（6.0%）或已知心血管疾病（CVD）患者（10.5%）的病死率显著较高。我们提出了一个生物学上的原因，在这些人群中的死亡率较高的风险是显而易见的。我们进一步提出了一组病理生理学原因的高度危险，可能会导致治疗，以加强管理和预防。
The majority of fatalities thus far in the COVID-19 pandemic have been attributed to pneumonia. As expected, the fatality rate reported in China is higher in people with chronic pulmonary disease (6.3%) and those who have cancer (5.6%). According to the American College of Cardiology Clinical Bulletin "COVID-19 Clinical Guidance for the CV Care Team", there is a significantly higher fatality rate in people who are elderly (8.0% 70-79 years; 14.8% >= 80 years), diabetic (7.3%), hypertensive (6.0%), or have known cardiovascular disease (CVD) (10.5%). We propose a biological reason for the higher mortality risk in these populations that is apparent. We further present a set of pathophysiological reasons for the heightened danger that could lead to therapies for enhanced management and prevention.